Systemic Radiotherapy

Systemic Radiotherapy

Global Systemic Radiotherapy Market to Reach US$1.1 Billion by 2030

The global market for Systemic Radiotherapy estimated at US$876.6 Million in the year 2023, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 3.9% over the analysis period 2023-2030. Hospitals End-Use, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$919.6 Million by the end of the analysis period. Growth in the Independent Radiotherapy Centers End-Use segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$233.2 Million While China is Forecast to Grow at 6.0% CAGR

The Systemic Radiotherapy market in the U.S. is estimated at US$233.2 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$238.5 Million by the year 2030 trailing a CAGR of 6.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Systemic Radiotherapy Market - Key Trends and Drivers Summarized

Why Is Systemic Radiotherapy Garnering Increasing Attention?

Systemic radiotherapy is emerging as a highly effective cancer treatment option, gaining increased attention for its ability to target cancer cells throughout the body using radioactive substances. Unlike traditional external beam radiotherapy, which focuses on specific localized tumors, systemic radiotherapy works by delivering radioactive isotopes directly into the bloodstream, allowing them to travel and treat cancers that have spread to multiple areas. This technique is particularly valuable in treating cancers such as thyroid cancer, neuroendocrine tumors, and certain types of bone metastases. The most commonly used isotopes include iodine-131, used for thyroid cancer, and lutetium-177, which has shown promise in targeting neuroendocrine tumors. Because the radiation is systemic, it reaches cancerous cells beyond the primary tumor site, making it an essential tool for managing metastatic cancers that are difficult to treat through localized methods. As cancer treatment continues to evolve, systemic radiotherapy is becoming a cornerstone of precision medicine, offering hope to patients with complex and widespread disease.

How Does Systemic Radiotherapy Cater to Complex Cancer Cases?

Systemic radiotherapy plays a pivotal role in addressing the complexities of metastatic and advanced-stage cancers, which often require more comprehensive treatment approaches. Patients with cancers that have spread beyond their primary tumor site pose a significant challenge, as localized treatments are not sufficient to target all cancerous areas. Systemic radiotherapy addresses this by circulating radioactive substances through the bloodstream, allowing the radiation to target both visible tumors and microscopic cancer cells that may not be detectable by imaging. For example, in the case of prostate cancer that has metastasized to the bones, systemic radiotherapy with radium-223 can specifically target bone metastases, alleviating pain and reducing the progression of the disease. Similarly, iodine-131 is highly effective for patients with thyroid cancer, even when the cancer has spread to distant organs such as the lungs or bones. Systemic radiotherapy’s ability to treat widespread cancer with precision offers a powerful alternative or adjunct to other treatment modalities like chemotherapy, surgery, or localized radiation therapy, particularly in cases where the cancer is aggressive or has already advanced to later stages.

What Technological Advancements Are Shaping Systemic Radiotherapy?

Recent technological advancements have significantly enhanced the efficacy and safety of systemic radiotherapy, contributing to its expanding role in cancer treatment. One of the most notable developments is the refinement of radiopharmaceuticals—the radioactive substances used in systemic radiotherapy. These substances are now more targeted, allowing them to attach specifically to cancer cells while minimizing exposure to healthy tissues. For instance, radioisotopes like lutetium-177 are bound to molecules that seek out and attach to cancer cells, ensuring that the radiation is delivered directly where it is needed. This targeted approach has reduced the side effects traditionally associated with radiation therapy, such as damage to surrounding healthy tissues. Another critical advancement is the improvement in imaging technologies, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), which allow clinicians to track the distribution of radioactive substances in the body in real time. This enables more precise dosing and personalized treatment plans, as doctors can adjust the therapy based on how the radiopharmaceuticals are distributed in the patient’s body. Additionally, innovations in dosimetry have improved the ability to calculate and deliver optimal radiation doses, ensuring that the treatment is both effective and safe for patients. These technological strides are making systemic radiotherapy a more viable and attractive option for a broader range of cancers, particularly those that are resistant to other forms of treatment.

What Are the Key Factors Driving the Growth of the Systemic Radiotherapy Market?

The growth in the systemic radiotherapy market is driven by several factors, primarily the increasing incidence of cancer and the demand for more effective treatments for advanced and metastatic cancers. As cancer rates continue to rise globally, there is a growing need for therapies that can target not only localized tumors but also widespread metastatic disease. Systemic radiotherapy addresses this need by offering a solution for cancers that have spread to multiple areas of the body, making it a critical treatment option for late-stage cancer patients. Another key driver is the shift toward personalized medicine, which has spurred the development of radiopharmaceuticals that target specific cancer cells based on their unique molecular markers. This has significantly increased the efficacy of systemic radiotherapy while reducing side effects, making it more appealing to both patients and healthcare providers. Additionally, regulatory approvals for new radiopharmaceuticals, such as the recent approval of lutetium-177 for treating neuroendocrine tumors, are expanding the potential applications of systemic radiotherapy. The growing use of advanced imaging technologies for precise treatment planning and monitoring is also contributing to the market’s growth, as these tools enable more accurate and personalized therapies. Moreover, there is a rising awareness and adoption of systemic radiotherapy in emerging markets, where access to advanced cancer treatments is increasing. Lastly, an aging population, which is more susceptible to cancer, is further fueling the demand for systemic radiotherapy as a critical component of cancer care. These combined factors are propelling the systemic radiotherapy market forward, offering new hope for cancer patients and driving innovation in this rapidly evolving field of oncology.

Select Competitors (Total 42 Featured) -

• Accuray, Inc.;Advanced Radiotherapy Consulting;Canon Medical Systems Corporation;Carl Zeiss Meditec AG;Centre for Probe Development and Commercialization;Eckert & Ziegler Radiopharma GmbH;Elekta AB;Galera Therapeutics;Hitachi Ltd.;iCAD, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.